Detalhe da pesquisa
1.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 186(16): 3476-3498.e35, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541199
2.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 187(4): 1016, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364782
3.
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Genes Dev
; 31(3): 318-332, 2017 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28242626
4.
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol
; 185: 83-94, 2024 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377762
5.
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer.
Oncologist
; 28(3): 252-257, 2023 03 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36718018
6.
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
Gynecol Oncol
; 172: 82-91, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001446
7.
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study.
Gynecol Oncol
; 171: 141-150, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36898292
8.
Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Gynecol Oncol
; 171: 151-158, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905875
9.
Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100.
Gynecol Oncol
; 178: 119-129, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37862791
10.
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer.
BMC Bioinformatics
; 23(1): 321, 2022 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35931981
11.
A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial.
Gynecol Oncol
; 167(3): 423-428, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36244829
12.
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.
Gynecol Oncol
; 164(2): 245-253, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34906376
13.
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors.
Int J Clin Oncol
; 27(12): 1881-1890, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36344654
14.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363762
15.
Inhibition of Kpnß1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.
BMC Cancer
; 21(1): 106, 2021 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33530952
16.
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer.
Gynecol Oncol
; 162(3): 661-666, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34243976
17.
Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Gynecol Oncol
; 161(2): 382-388, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33712274
18.
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Int J Cancer
; 147(2): 413-422, 2020 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31714586
19.
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer.
Gynecol Oncol
; 156(2): 301-307, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31870556
20.
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Gynecol Oncol
; 157(1): 161-166, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31924334